Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic-drug specialist Momenta Pharmaceuticals (Nasdaq: MNTA) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Momenta's business and see what CAPS investors are saying about the stock right now.

Momenta facts

   
Headquarters (Founded) Cambridge, Mass. (2001)
Market Cap $587.4 million
Industry Biotechnology
Trailing-12-Month Revenue $64.09 million
Management

CEO Craig Wheeler (since 2006)

CFO Richard Shea (since 2003)

Return on Equity (Average, Past 3 Years) (45.4%)
Cash/Debt $65.7 million / $3.1 million
Competitors

sanofi-aventis (NYSE: SNY)

Teva Pharmaceuticals (Nasdaq: TEVA)
Watson Pharmaceuticals (NYSE: WPI)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 93% of the 437 members who have rated Momenta believe the stock will outperform the S&P 500 going forward. These bulls include dtor and All-Star TSIF, who is ranked in the top 0.5% of our community.

Just last week, dtor noted that Momenta "has spent almost 10 years developing the infrastructure to produce new generics on [almost] an assembly line basis." Our CAPS member concludes: "Traditional numbers on [generic] market share don't apply -- their technology forms a VERY LARGE moat."

Currently, Momenta trades at a forward P/E of 6.9. That's a discount to competitors sanofi (7.6), Teva (10.2), and Watson (13.4), as well as big pharma plays like Pfizer (NYSE: PFE) (8.5) and Merck (NYSE: MRK) (8.6).

CAPS All-Star TSIF elaborates on the bargain opportunity:

It dropped 30% on word that [Teva] received an FDA response from the FDA on a generic version of Momenta's only current drug, Lovenox. Teva reported that FDA questions appeared to be miner. ...

Complete responses, even if minor take time and Momenta may delay [Teva] production further by pursuing patent litigation, (which they are unlikely to win, but could use to delay). Any delay is pure cash to Momenta's balance sheet. In the meantime, Momenta will continue to build out its generic portolio, most likely with a play back against [Teva] on one of their current drugs, [Copaxone] for multiple sclerosis. This could be a long term play waiting for one of several possible catalysts, or it could be an exit on another mood swing.

What do you think about Momenta, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Momenta is a Motley Fool Rule Breakers recommendation. Pfizer is an Inside Value pick. The Fool owns shares of Teva. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.